Canaccord analyst George Gianarikas lowered the firm’s price target on Aspen Aerogels (ASPN) to $5 from $10 and keeps a Buy rating on the shares. The firm said with a solid balance sheet and minimal capital expenditure needs, liquidity is expected to remain healthy. And looking past 2026, they expect a return to healthy levels of EBITDA with material flow through to free cash flow.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASPN: